0001096906-26-000507
SEC filingDeepening losses marked FY2025 as WEED, Inc. reported zero revenue while general and administrative expenses more than tripled due to salary increases, prioritizing genetics cataloging and asset preservation amid operating cash burn.
Management's Item 7 discussion highlights focus on cataloging proprietary cannabis genetics throughout 2025 to underpin future pharmaceutical research and consumer products. These assets, acquired via prior Hempirical transaction, carry cost-basis accounting but hold 'significant long-term strategic value' as federal cannabis regulations evolve—positioning WEED for potential pharma and branded plays without current monetization.
Liquidity remains strained, with net cash used in operations improving to -$195K from -$416K yet insufficient to stem negative cash flows from persistent losses. The company did not generate positive operating cash flows in either 2025 or 2024, necessitating capital raises to meet obligations. Increases in related-party notes payable supported operations amid severely restricted capital market access, as flagged in Item 1A Risk Factors, where federal illegality and funding barriers pose existential threats to business plans.
Balance sheet contraction reflects asset preservation mode: total assets declined due to cash reductions, ROU asset depletion, and accumulated depreciation. Deregistration of overseas subsidiaries trimmed overhead, while new initiatives like WEEDCoin/BUDZCoin via Remergify partnership target cannabis banking and supply chain gaps—early efforts to enable global ambitions in research, marketing, import/export, and manufacturing.
Overall, FY2025 emphasized non-revenue priorities over profitability, with management banking on genetics and crypto innovations for turnaround. However, without capital infusion, ongoing losses and liquidity pressures could hinder execution, particularly given regulatory headwinds and no near-term revenue catalysts.